Alternative splicing is a widespread process contributing to structural transcript variation and
proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both …

For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been
shown to exert oncogenic activity. These two proteins are best understood as negative …

Purpose: We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized,
cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and …

The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors
mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog …

Background Gene expression profiling is being widely applied in cancer research to identify
biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for …

Osteosarcoma is a relatively uncommon cancer, accounting for 5% of childhood cancers
and 8.9% of cancer-related deaths in children. The overall incidence is five cases per million …

Genomic and functional study of existing and emerging sarcoma targets, such as fusion
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …

MDM4 is a promising target for cancer therapy, as it is undetectable in most normal adult
tissues but often upregulated in cancer cells to dampen p53 tumor-suppressor function. The …

Osteosarcoma is an aggressive cancer in skeletal system with unknown molecular
mechanisms of etiology and pathogenesis, therefore it remains a challenge for current …

Merkel cell polyomavirus (MCV) contributes to approximately 80% of all Merkel cell
carcinomas (MCCs), a highly aggressive neuroendocrine carcinoma of the skin. MCV …